亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

無錫同創生物科技有限公司  

辣根過氧化物酶,5-溴-4氯-3吲哚-神經氨酸,吡咯酯等

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:張倩
  • 電話:13655185676
  • 郵件:wuxitongchuang@yahoo.cn
  • 傳真:0510-85899582
  • QQ:1760363918
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 同創批發供應 5-溴-4-氯-3-吲哚-磷酸鹽
同創批發供應 5-溴-4-氯-3-吲哚-磷酸鹽
單價 面議對比
詢價 暫無
發貨 江蘇無錫市付款后3天內
品牌 無錫同創
型號 6578-06-9
規格 5G/瓶
過期 長期有效
更新 2024-01-10 11:53
 
詳細信息

【中文名】5-溴-4-氯-3-吲哚基磷酸酯對甲苯胺鹽, 5-溴-4-氯-3-吲哚-磷酸鹽
【英文名】5-Bromo-4-Chloro-3-Indolyl Phosphate
【分子式】C8H6BrClNO4P·C7H9N
【分子量】433.62
CAS6578-06-9
含量:≥99.0%
【外觀】灰白色粉末
【用途】BCIP+NBT(四唑硝基藍)是堿性磷酸酶最佳的底物組合之一, 產物為深藍色. 在堿性磷酸酯酶的催化下,BCIP會被水解產生強反應性的產物,該產物會和NBT發生反應,形成不溶性的深藍色至藍紫色的NBT-formazan。NBT/BCIP染色試劑盒用于蛋白印跡和免疫組化等染色。也可以用于細胞或組織內源性的堿性磷酸酯酶顯色。
©2025 無錫同創生物科技有限公司 版權所有   技術支持:化工網   訪問量:36576  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |